Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN9708 + lenalidomide + dexamethasone induction/consolidation with MLN9708 maintenance in young, newly diagnosed multiple myeloma
2013-001443-31Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: stringent complete response rate at completion of consolidation. Started Jun 2015; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-001443-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001443-31.